A randomized, cross-over study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian with single and dual antiplatelet therapy in healthy participants

Back

ESC Professional Premium Access

A randomized, cross-over study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian with single and dual antiplatelet therapy in healthy participants

Session: Challenges and advances in antithrombotic therapy

Topic: Anticoagulants

Speaker: Doctor G. Abelian (US)

Event: ESC Congress 2022

Congress Presentation

About the speaker

Doctor Grigor Abelian

(United States of America)

2 followers

6 more presentations in this session

Effect of low-dose rivaroxaban with low-dose aspirin vs low-dose aspirin on platelet and oxidative biomarkers: a randomized study in diabetes patients with stable peripheral or coronary artery disease

Speaker: Associate Professor B. Rocca (Rome, IT)

Access

Abstract

Slides

Antithrombotic strategies in antiphospholipid syndrome with arterial thrombosis: a systematic review and network meta-analysis

Speaker: Doctor T. Attachaipanich (Chiang Mai, TH)

Access

Abstract

Slides

Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study

Speaker: Doctor K. Matli (Beirut, LB)

Access

Abstract

Slides

CS014 is a novel HDAC inhibitor regulating the platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding

Speaker: Associate Professor M. Holinstat (Ann Arbor, US)

Access

Abstract

Slides

Aspirin therapy on prophylactic anticoagulation for hospitalized patients with COVID-19: A propensity score-matched cohort analysis of the HOPE-COVID-19 registry.

Speaker: Doctor F. Santoro (Foggia, IT)

Access

Abstract

Slides

Access the full session

Challenges and advances in antithrombotic therapy

Speakers: Doctor G. Abelian, Associate Professor B. Rocca, Doctor T. Attachaipanich, Doctor K. Matli, Associate Professor M. Holinstat...

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

A randomized, cross-over study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian with single and dual antiplatelet therapy in healthy participants

About the speaker

Doctor Grigor Abelian

6 more presentations in this session

Effect of low-dose rivaroxaban with low-dose aspirin vs low-dose aspirin on platelet and oxidative biomarkers: a randomized study in diabetes patients with stable peripheral or coronary artery disease

Antithrombotic strategies in antiphospholipid syndrome with arterial thrombosis: a systematic review and network meta-analysis

Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study

CS014 is a novel HDAC inhibitor regulating the platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding

Aspirin therapy on prophylactic anticoagulation for hospitalized patients with COVID-19: A propensity score-matched cohort analysis of the HOPE-COVID-19 registry.

Access the full session

Challenges and advances in antithrombotic therapy

About the event

ESC Congress 2022

ESC 365 is supported by